Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17138309 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | December 2020 | September 2024 | Allow | 45 | 3 | 1 | Yes | No |
| 17130580 | METHODS OF TREATING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) DYSFUNCTION | December 2020 | December 2023 | Allow | 36 | 2 | 1 | No | No |
| 17253737 | CYANOTRIAZOLE COMPOUNDS AND USES THEREOF | December 2020 | December 2023 | Abandon | 36 | 0 | 1 | No | No |
| 17124242 | ANTI-NEOPLASTIC COMPOUNDS AND METHODS TARGETING QSOX1 | December 2020 | April 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17114169 | FORMULATIONS FOR CGRP RECEPTOR ANTAGONISTS | December 2020 | August 2023 | Abandon | 32 | 1 | 0 | No | No |
| 17108065 | HIGH-DOSE STATINS FOR AGE-RELATED MACULAR DEGENERATION | December 2020 | June 2023 | Allow | 30 | 1 | 0 | No | No |
| 17101286 | COMPOUNDS AND METHODS FOR REPELLING BLOOD-FEEDING ARTHROPODS AND DETERRING THEIR LANDING AND FEEDING | November 2020 | May 2023 | Abandon | 30 | 1 | 0 | No | No |
| 17052882 | Test to distinguish viral-only from bacterial infection or viral/bacterial coinfection using a respiratory swab | November 2020 | July 2024 | Allow | 44 | 1 | 1 | No | No |
| 17087144 | COMPOUNDS CONTAINING CARBON-CARBON LINKER AS GPR120 AGONISTS | November 2020 | May 2023 | Allow | 30 | 1 | 1 | No | No |
| 17051060 | THE USE OF SGC ACTIVATORS AND SGC STIMULATORS FOR THE TREATMENT OF COGNITIVE IMPAIRMENT | October 2020 | June 2024 | Abandon | 44 | 3 | 1 | No | No |
| 17061743 | RET INHIBITOR FOR USE IN TREATING CANCER HAVING A RET ALTERATION | October 2020 | December 2023 | Allow | 38 | 1 | 0 | No | No |
| 17043966 | METHODS FOR MITIGATING AND PREVENTING PROTEOSTASIS-BASED INJURIES | September 2020 | April 2024 | Abandon | 42 | 2 | 1 | No | No |
| 16982772 | FORMULATIONS AND COMPOSITIONS OF DOCETAXEL | September 2020 | December 2024 | Abandon | 51 | 1 | 1 | No | No |
| 17022669 | TREATMENT OF POULTRY, PIGS OR FISH FOR REDUCING THE FEED CONVERSION RATIO OR INCREASING THEIR BODYWEIGHT GAIN | September 2020 | August 2023 | Abandon | 35 | 2 | 0 | No | No |
| 17021185 | Methods for Treating Mucopolysaccharidosis | September 2020 | February 2024 | Allow | 41 | 4 | 0 | Yes | No |
| 17018143 | METHODS TO PREDICT CLINICAL OUTCOME OF CANCER | September 2020 | June 2024 | Abandon | 45 | 0 | 1 | No | No |
| 16978442 | 17-BETA-HYDROXYWITHANOLIDES AND USE THEREOF IN TREATING CANCER | September 2020 | July 2023 | Abandon | 35 | 1 | 1 | No | No |
| 16976638 | POLYETHER-BASED BLOCK COPOLYMERS HAVING HYDROPHOBIC DOMAINS | August 2020 | August 2024 | Abandon | 48 | 1 | 1 | No | No |
| 16990515 | SYNERGISTIC FORMULATIONS FOR CONTROL AND REPELLENCY OF BITING ARTHROPODS | August 2020 | September 2023 | Allow | 38 | 2 | 1 | No | No |
| 16943821 | COMBINATION THERAPY FOR THE TREATMENT OF GASTROINTESTINAL STROMAL TUMOR | July 2020 | January 2024 | Allow | 41 | 2 | 1 | No | No |
| 16937810 | CAPSAICINOIDS FOR USE IN TREATING ACRAL LICK GRANULOMA | July 2020 | August 2023 | Abandon | 36 | 2 | 0 | No | No |
| 16926992 | GLUCURONIDE PRODRUGS OF JANUS KINASE INHIBITORS | July 2020 | March 2024 | Abandon | 44 | 1 | 0 | No | No |
| 16923197 | DIAZOLE LACTAMS | July 2020 | July 2023 | Allow | 36 | 2 | 1 | No | No |
| 16956330 | ANTIBIOTIC THERAPY GUIDANCE BASED ON PROCALCITONIN IN PATIENTS WITH COMORBIDITIES | June 2020 | July 2024 | Allow | 49 | 4 | 1 | Yes | No |
| 16768991 | TREATMENT OF POST-TRAUMATIC SYNDROME DISORDER | June 2020 | June 2024 | Abandon | 49 | 3 | 1 | No | No |
| 16766696 | COMPOUND FOR USE IN THE INCREASING OF MENTAL CAPABILITY | May 2020 | April 2024 | Abandon | 47 | 3 | 1 | No | No |
| 16651826 | ANTI-INFLAMMATORY, ANTI-CANCER, AND ANTI-ANGIOGENIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THEREOF | March 2020 | April 2023 | Allow | 37 | 2 | 1 | No | No |
| 16833106 | ASSESSMENT OF BIOLOGICAL CONTAMINATION AND BIOLOGICAL CONTAMINATION TREATMENT | March 2020 | July 2024 | Allow | 51 | 4 | 1 | Yes | No |
| 16650526 | IMPROVED ANIMAL FEED COMPOSITIONS AND METHODS OF USE | March 2020 | June 2023 | Allow | 39 | 2 | 1 | No | No |
| 16818343 | MATTER OF COMPOSITION, SYNTHESIS, FORMULATION AND APPLICATION OF FL118 PLATFORM POSITIONS 7 AND 9-DERIVED ANALOGUES FOR TREATMENT OF HUMAN DISEASE | March 2020 | June 2024 | Allow | 52 | 8 | 2 | Yes | Yes |
| 16641524 | COMPOSITION COMPRISING SUPLATAST TOSILATE | February 2020 | June 2023 | Allow | 39 | 2 | 1 | No | No |
| 16790395 | TOPICAL COMPOSITIONS AND METHODS OF FORMULATING THE SAME | February 2020 | December 2023 | Abandon | 46 | 5 | 1 | No | Yes |
| 16697888 | DARUNAVIR COMBINATION FORMULATIONS | November 2019 | January 2023 | Allow | 37 | 2 | 1 | Yes | No |
| 16603031 | PHARMACEUTICAL COMPOSITION COMPRISING LENVATINIB MESYLATE | October 2019 | October 2023 | Allow | 49 | 3 | 1 | Yes | Yes |
| 16489212 | AGENT ENHANCING ANTITUMOR EFFECT USING PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND | August 2019 | February 2023 | Allow | 42 | 2 | 1 | No | No |
| 16518226 | METHODS FOR TREATING VIRAL DISORDERS | July 2019 | February 2023 | Allow | 43 | 3 | 1 | No | No |
| 16473437 | APPLICATION OF COMBINATION OF POLYETHYLENE GLYCOL AND LOCAL ANESTHETIC IN NON-NARCOTIC ANALGESIA | June 2019 | January 2023 | Allow | 43 | 3 | 2 | No | No |
| 16466931 | ASCORBIC ACID AND QUINONE COMPOUNDS FOR TREATING CHAGAS DISEASE | June 2019 | January 2024 | Allow | 56 | 7 | 1 | No | Yes |
| 16343690 | PHARMACEUTICAL COMPOSITIONS | April 2019 | February 2023 | Allow | 46 | 4 | 2 | Yes | No |
| 16342695 | METHODS OF INHIBITING VIRUSES USING COMPOSITIONS TARGETING TSG101-UBIQUITIN INTERACTION | April 2019 | April 2024 | Allow | 60 | 6 | 2 | No | No |
| 16243234 | TRANEXAMIC ACID ORAL SOLUTION | January 2019 | January 2023 | Allow | 48 | 5 | 1 | Yes | No |
| 16243253 | METHODS OF REDUCING OR PREVENTING OXIDATION OF LDL OR LIPID MEMBRANES IN A SUBJECT IN NEED THEREOF | January 2019 | May 2023 | Abandon | 52 | 6 | 0 | No | No |
| 16206747 | METHODS FOR IMPROVING RESISTANCE TO SKELETAL MUSCLE FATIGUE | November 2018 | April 2023 | Abandon | 52 | 5 | 1 | No | No |
| 16084075 | UNIT DOSES FOR IMMEDIATE RELEASE OF GHB OR OF ONE OF THE THERAPEUTICALLY ACCEPTABLE SALTS THEREOF, ADMINISTERED ORALLY, AND THE USE THEREOF TO MAINTAIN ALCOHOL ABSTINENCE | September 2018 | February 2023 | Allow | 53 | 2 | 1 | Yes | Yes |
| 16053383 | LOXAPINE FILM ORAL DOSAGE FORM | August 2018 | January 2023 | Allow | 54 | 5 | 1 | No | Yes |
| 16064024 | METHOD FOR MANAGING RESISTANCE TO INSECTICIDAL TRAITS AND CHEMICALS USING PHEROMONES | June 2018 | September 2023 | Allow | 60 | 4 | 1 | Yes | No |
| 15765854 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF RETINAL CAPILLARY NON-PERFUSION | April 2018 | March 2024 | Allow | 60 | 8 | 0 | Yes | No |
| 15758153 | METHODS AND COMPOSITIONS FOR SOFT ANTICHOLINERGIC ZWITTERIONS | March 2018 | May 2019 | Abandon | 15 | 0 | 1 | No | No |
| 15898683 | PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATIONS THEREOF | February 2018 | October 2019 | Abandon | 20 | 1 | 0 | No | No |
| 15889714 | COMPOSITIONS AND METHODS FOR TREATING CONDITIONS RELATED TO ELEVATED LEVELS OF EOSINOPHILS AND/OR BASOPHILS | February 2018 | April 2019 | Allow | 14 | 1 | 0 | No | No |
| 15737985 | SACUBITRIL CALCIUM SALTS | December 2017 | June 2023 | Allow | 60 | 5 | 1 | No | Yes |
| 15674357 | COMPOSITION AND METHOD FOR MUSCLE REPAIR AND REGENERATION | August 2017 | January 2019 | Allow | 17 | 2 | 0 | No | No |
| 15667483 | METHODS FOR THE TREATMENT OF ABNORMAL INVOLUNTARY MOVEMENT DISORDERS | August 2017 | January 2023 | Allow | 60 | 8 | 0 | Yes | Yes |
| 15543966 | CHLOROPHYLL COMPOSITION | July 2017 | September 2024 | Allow | 60 | 10 | 2 | No | No |
| 15543510 | COMBINATION THERAPY FOR PULMONARY HYPERTENSION | July 2017 | June 2019 | Abandon | 23 | 1 | 0 | No | No |
| 15643182 | PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATIONS THEREOF | July 2017 | April 2019 | Abandon | 21 | 0 | 1 | No | No |
| 15599890 | DETRUSOR HYPERACTIVITY WITH IMPAIRED CONTRACTILITY AMELIORATING AGENT | May 2017 | April 2019 | Abandon | 23 | 1 | 0 | No | No |
| 15581134 | FORMULATIONS OF CYCLOPHOSPHAMIDE LIQUID CONCENTRATE | April 2017 | November 2019 | Abandon | 31 | 2 | 1 | No | No |
| 15428868 | METHODS FOR THE TREATMENT OF ABNORMAL INVOLUNTARY MOVEMENT DISORDERS | February 2017 | April 2019 | Abandon | 26 | 3 | 0 | Yes | No |
| 15426454 | NOVEL USES | February 2017 | October 2019 | Abandon | 32 | 2 | 0 | No | No |
| 15407497 | NOVEL ESTROGEN RECEPTOR LIGANDS | January 2017 | October 2019 | Abandon | 33 | 2 | 1 | No | No |
| 15398584 | THERAPEUTIC COMPOUNDS | January 2017 | April 2019 | Allow | 27 | 2 | 1 | Yes | No |
| 15374013 | AMINOPYRIMIDINE KINASE INHIBITORS | December 2016 | January 2019 | Allow | 26 | 1 | 1 | No | No |
| 15342783 | EXTENDED-RELEASE FORMULATION FOR REDUCING THE FREQUENCY OF URINATION AND METHOD OF USE THEREOF | November 2016 | October 2019 | Abandon | 35 | 2 | 1 | No | No |
| 15331360 | METHODS FOR TREATING FEMALE SEXUAL DYSFUNCTION WHILE DECREASING CARDIOVASCULAR RISK | October 2016 | June 2018 | Abandon | 19 | 0 | 1 | No | No |
| 15287019 | METHOD OF WEIGHT MANAGEMENT | October 2016 | May 2018 | Abandon | 20 | 1 | 0 | No | No |
| 15277485 | SYNERGISTIC ANTIMICROBIAL COMPOSITION | September 2016 | September 2018 | Abandon | 24 | 2 | 0 | No | Yes |
| 15276824 | BIOCIDAL COMPOSITIONS AND METHODS OF USE | September 2016 | January 2018 | Allow | 16 | 2 | 0 | No | No |
| 15227787 | FORMULATIONS AND USES FOR MICROPARTICLE DELIVERY OF METALLOPORPHYRINS | August 2016 | June 2019 | Abandon | 34 | 2 | 1 | No | No |
| 15220574 | FLUORINATED ARYLALKYLAMINOCARBOXAMIDE DERIVATIVES | July 2016 | February 2019 | Abandon | 30 | 2 | 1 | No | No |
| 15198574 | FUNGICIDAL BARK SPRAYS FOR TREES | June 2016 | July 2018 | Abandon | 25 | 2 | 0 | No | No |
| 15106285 | SUBSTITUTED BIPIPERIDINYL DERIVATIVES | June 2016 | June 2018 | Abandon | 24 | 1 | 1 | No | No |
| 15104284 | DRY ENEMA PRODUCT | June 2016 | June 2018 | Abandon | 24 | 2 | 0 | No | No |
| 15103595 | Sulfamate Derivative Compounds for Use in Treating or Alleviating Pain | June 2016 | May 2018 | Allow | 23 | 1 | 1 | No | No |
| 15176788 | CRYSTALLINE FORMS OF A HISTONE DEACETYLASE INHIBITOR | June 2016 | June 2019 | Allow | 36 | 3 | 1 | No | Yes |
| 15155526 | DETRUSOR HYPERACTIVITY WITH IMPAIRED CONTRACTILITY AMELIORATING AGENT | May 2016 | November 2016 | Allow | 7 | 1 | 0 | No | No |
| 15150497 | FORMULATIONS OF AZAINDOLE COMPOUNDS | May 2016 | October 2018 | Abandon | 29 | 2 | 1 | No | No |
| 15034295 | Compositions and Methods For Treating Brain Injury and Brain Diseases | May 2016 | March 2018 | Abandon | 22 | 1 | 1 | No | No |
| 15134509 | METHOD OF TREATING IDIOPATHIC PULMONARY FIBROSIS | April 2016 | December 2016 | Abandon | 8 | 0 | 0 | No | No |
| 15082565 | Method for Treating Addiction | March 2016 | March 2018 | Abandon | 23 | 1 | 1 | No | No |
| 15024169 | INHIBITORS OF POLYNUCLEOTIDE REPEAT-ASSOCIATED RNA FOCI AND USES THEREOF | March 2016 | May 2018 | Allow | 26 | 1 | 1 | No | No |
| 15021471 | FORMULATIONS FOR CGRP RECEPTOR ANTAGONISTS | March 2016 | September 2019 | Abandon | 43 | 2 | 1 | No | No |
| 15063068 | METHODS FOR THE TREATMENT OF ABNORMAL INVOLUNTARY MOVEMENT DISORDERS | March 2016 | October 2018 | Abandon | 31 | 2 | 1 | Yes | No |
| 15048933 | Anti-Allergy Benzocycloheptathiophene Derivatives | February 2016 | March 2018 | Allow | 25 | 2 | 1 | No | No |
| 15012307 | Waxes Derived from Metathesized Natural Oils and Amines and Methods of Making | February 2016 | September 2017 | Allow | 19 | 1 | 1 | No | No |
| 14906868 | ORALLY DISINTEGRATING FILM PREPARATION CONTAINING DONEPEZIL OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PREPARATION METHOD THEREFOR | January 2016 | October 2019 | Abandon | 44 | 3 | 1 | No | No |
| 14997248 | Purinone Derivatives as Tyrosine Kinase Inhibitors | January 2016 | March 2018 | Abandon | 26 | 2 | 1 | No | No |
| 14975123 | Compositions and Methods for Treating an Infection | December 2015 | September 2018 | Abandon | 33 | 3 | 1 | Yes | No |
| 14971928 | Formulations for the Treatment of Deep Tissue Pain | December 2015 | August 2018 | Abandon | 32 | 2 | 1 | No | No |
| 14968711 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | December 2015 | March 2018 | Abandon | 27 | 2 | 0 | No | No |
| 14941867 | Opioid Agonist Antagonist Combinations | November 2015 | September 2018 | Allow | 34 | 3 | 1 | No | No |
| 14888314 | METHODS FOR ENHANCING AGED MUSCLE REGENERATION | October 2015 | April 2019 | Abandon | 41 | 4 | 1 | No | No |
| 14873919 | EXTENDED-RELEASE FORMULATION FOR REDUCING THE FREQUENCY OF URINATION AND METHOD OF USE THEREOF | October 2015 | January 2017 | Abandon | 16 | 0 | 1 | No | No |
| 14778497 | ROR GAMMA MODULATORS | September 2015 | May 2019 | Abandon | 44 | 3 | 1 | No | No |
| 14852996 | Novel Use of Adapalene in Treating Esophageal Cancer and Gastrointestinal Stromal Tumor | September 2015 | October 2016 | Abandon | 14 | 1 | 0 | No | No |
| 14848179 | TREATMENT OF CANCER AND OTHER CONDITIONS USING A TRANSCRIPTION FACTOR MODULATOR | September 2015 | October 2016 | Abandon | 14 | 0 | 1 | No | No |
| 14772317 | HDAC INHIBITORS FOR THE TREATMENT OF TRAUMATIC BRAIN INJURY | September 2015 | February 2018 | Abandon | 29 | 2 | 1 | No | No |
| 14769017 | PHARMACEUTICAL COMPOSITIONS OF CETP INHIBITORS | August 2015 | September 2018 | Abandon | 37 | 3 | 1 | No | No |
| 14819024 | METHODS FOR TREATING VIRAL DISORDERS | August 2015 | October 2019 | Abandon | 50 | 4 | 1 | No | No |
| 14817318 | DETRUSOR HYPERACTIVITY WITH IMPAIRED CONTRACTILITY AMELIORATING AGENT | August 2015 | January 2017 | Abandon | 18 | 0 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner LEE, ANDREW P.
With a 66.7% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 20.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner LEE, ANDREW P works in Art Unit 1621 and has examined 293 patent applications in our dataset. With an allowance rate of 40.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 34 months.
Examiner LEE, ANDREW P's allowance rate of 40.3% places them in the 8% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by LEE, ANDREW P receive 2.63 office actions before reaching final disposition. This places the examiner in the 73% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by LEE, ANDREW P is 34 months. This places the examiner in the 42% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +26.9% benefit to allowance rate for applications examined by LEE, ANDREW P. This interview benefit is in the 73% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 16.0% of applications are subsequently allowed. This success rate is in the 14% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 24.2% of cases where such amendments are filed. This entry rate is in the 34% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 128.6% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 85% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 87.5% of appeals filed. This is in the 80% percentile among all examiners. Of these withdrawals, 61.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 67.9% are granted (fully or in part). This grant rate is in the 74% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 0% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.